Trial Profile
Phase II trial of the addition of bevacizumab to alectinib beyond progressive disease in ALK-positive advanced non-small-cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Oct 2019
Price :
$35
*
At a glance
- Drugs Alectinib (Primary) ; Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer
- 22 Feb 2019 Status changed from recruiting to completed.
- 10 Jun 2015 New trial record